Related references
Note: Only part of the references are listed.CERA corrects anemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial
Iain C. Macdougall et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin δ
Bruce S. Spinowitz
HAEMATOLOGICA (2008)
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes
Lynda A. Szczech et al.
KIDNEY INTERNATIONAL (2008)
European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)
Carmine Zoccali et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death
Areef Ishani et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Intravenous CERA maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study
Bernard Canaud et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
The normal hematocrit study - Follow-up
Anatole Besarab et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay
Michael Jarsch et al.
PHARMACOLOGY (2008)
Hemoglobin variability and mortality in ESRD
Wei Yang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis:: a randomised non-inferiority trial (MAXIMA)
Nothan W. Levin et al.
LANCET (2007)
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model
Kathryn W. Woodburn et al.
EXPERIMENTAL HEMATOLOGY (2007)
Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly
Wladyslaw Sulowicz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease
Anatole Besarab et al.
CLINICAL THERAPEUTICS (2007)
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study
Daniel W. Coyne et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis
Arintaya Phrommintikul et al.
LANCET (2007)
Continuous Erythropoietin Receptor Activator (CERA) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study
A. L. M. De Francisco et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in patients with chronic kidney disease
Iain C. Macdougall et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
Iain C. Macdougall et al.
LANCET (2006)
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
CL Bennett et al.
BLOOD (2005)
Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease
TCH Mix et al.
AMERICAN HEART JOURNAL (2005)
The burden of kidney disease: Improving global outcomes
G Eknoyan et al.
KIDNEY INTERNATIONAL (2004)
Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials
GFM Strippoli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Differentiating factors between erythropoiesis-stimulating agents - A guide to selection for anaemia of chronic kidney disease
R Deicher et al.
DRUGS (2004)
Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity?
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2003)
Hemoglobin variability in epoetin-treated hemodialysis patients
JS Berns et al.
KIDNEY INTERNATIONAL (2003)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
